Effects of remazolam on postoperative cognition and intraoperative cerebral oxygen in patients with valve disease

Effects of remazolam on postoperative delirium and intraoperative cerebral oxygen in patients with valve disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063387

Enrollment

Unknown

Registered

2022-09-05

Start date

2022-08-20

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac valve disease

Interventions

research team:Remazolam 0.4mg/kg was induced and maintained at 1mg/kg.h

Conrol group:Propofol 1.5 - 2.5mg/kg induced

Propofol 6-12mg / kg.h maintenance

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are scheduled to receive valve replacement surgery have no contraindications; 2. Age from 18 to 65, no gender limitation

Exclusion criteria

Exclusion criteria: 1. unable to communicate before surgery, such as coma, language barrier, etc. 2. preoperative history of mental illness, mental disorder or documented encephalopathy (such as cerebral infarction, brain tumor, hydrocephalus), etc. 3. Baseline MMSE score below 24. 4. Allergic to remazolam benzenesulfonic acid or its excipients, such as lactose, dextran, hydrochloric acid.

Design outcomes

Primary

Measure	Time frame
cam;	—

Secondary

Measure	Time frame
Cerebral oxygen saturation;	—

Countries

China

Contacts

Public ContactZhijian Li

the Second Xiangya Hospital, Central South University

1097146961@qq.com+86 17760499852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026